Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells

Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity

(2014) S. M. Offer et al.   CANCER RESEARCH

Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

(2014) Dan Rosmarin et al.   JOURNAL OF CLINICAL ONCOLOGY

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination

(2013) Dick Pluim et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

(2013) M C van Staveren et al.   PHARMACOGENOMICS JOURNAL

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

(2011) M. J. Deenen et al.   CLINICAL CANCER RESEARCH

The European Medicines Agency Review of Tegafur/Gimeracil/Oteracil (Teysuno ) for the Treatment of Advanced Gastric Cancer When Given in Combination with Cisplatin: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use (CHMP)

(2011) P. Matt et al.   ONCOLOGIST

Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?

(2010) Joseph Ciccolini et al.   Clinical Colorectal Cancer

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

(2010) André B. P. van Kuilenburg et al.   HUMAN GENETICS

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

(2009) Robert S. Jansen et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY